Swapnil Bhargava

Swapnil is the Chief Technical Officer at CG Oncology. He is responsible for building CMC functions including process development, MSAT, manufacturing, regulatory filings, and optimal delivery of cretostimogene grenadenorepvec for clinical studies and commercial supply following approval. He has supported multiple INDs and BLAs and has contributed to bringing multiple modalities to clinic and market: before joining CG Oncology, Swapnil was the Senior Vice President of CMC Development and GMP Manufacturing at AbCellera, leading the TechOps team. Prior to that, he was the VP for drug substance process development at SeaGen. There he was responsible for leading cell line development, upstream, downstream and conjugation process development and analytical sciences departments for early and late-stage drug development. Earlier, while at Amgen, he had led process development efforts for different modalities, including biosimilars. Swapnil has a doctorate in Chemical Engineering from University of Maryland and a BS/MS from the Indian Institute of Technology (IIT) Delhi.